India decries US 'arm twisting' tactics over Nexavar compulsory licence
This article was originally published in Scrip
Recent comments by the US deputy under secretary of commerce for intellectual property and deputy director of the US Patent and Trademark Office (PTO) Teresa Stanek Rea expressing "dismay and surprise" over India's granting of a compulsory licence for Bayer's anticancer Nexavar (sorafenib tosylate), and her suggestion that approaching the World Trade Organization (WTO) could be one of the "tools in the toolkit" to remedy it, have been strongly criticised in India as US pressure tactics driven by "domestic compulsions".
You may also be interested in...
Strong showing by Dr Reddy’s in Europe in fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. China growth strategy 'still valid', management maintains.
Informa Markets’ recent webinar on COVID-19 and its impact on the Indian pharmaceutical industry deliberated a range of burning issues across the sector’s spectrum of activities, including efforts to stem India’s vulnerable dependency on active pharmaceutical ingredients imported from China, current trends for the excipients and pharma machinery segments and how industry is handling demand-supply disruptions in these challenging times.
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.